The Manufacturers Life Insurance Company grew its stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 347.7% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 75,310 shares of the company's stock after buying an additional 58,488 shares during the period. The Manufacturers Life Insurance Company owned 0.12% of Cullinan Therapeutics worth $1,070,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in CGEM. Quantinno Capital Management LP boosted its holdings in Cullinan Therapeutics by 50.6% in the first quarter. Quantinno Capital Management LP now owns 72,282 shares of the company's stock valued at $1,027,000 after acquiring an additional 24,281 shares during the last quarter. Knott David M Jr acquired a new stake in Cullinan Therapeutics during the first quarter worth about $344,000. Dimensional Fund Advisors LP raised its holdings in shares of Cullinan Therapeutics by 6.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 906,028 shares of the company's stock worth $12,870,000 after purchasing an additional 57,259 shares during the period. AlphaCentric Advisors LLC raised its holdings in shares of Cullinan Therapeutics by 5.7% in the 1st quarter. AlphaCentric Advisors LLC now owns 20,135 shares of the company's stock worth $286,000 after purchasing an additional 1,094 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Cullinan Therapeutics in the 1st quarter valued at about $1,356,000. 86.31% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 8,000 shares of the company's stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $17.82, for a total value of $142,560.00. Following the completion of the transaction, the insider directly owned 162,844 shares of the company's stock, valued at $2,901,880.08. This represents a 4.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 8.60% of the stock is currently owned by insiders.

Cullinan Therapeutics News Summary

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $30 target for Cullinan Therapeutics (CGEM). The target remains meaningfully above the recent share price, providing a bullish valuation signal and likely supporting the stock’s recent strength.
• Neutral Sentiment: The analyst expects Cullinan to remain unprofitable but sees quarterly losses narrowing gradually in 2027, with estimated EPS of $(0.77) in Q1, $(0.78) in Q2, $(0.80) in Q3 and $(0.82) in Q4. Full-year 2027 EPS is projected at $(3.17), compared with an estimated $(3.53) loss in 2026.
• Neutral Sentiment: A reported short-interest figure of zero shares and a zero-day days-to-cover ratio offers no meaningful indication of bearish positioning. The data appears unreliable or incomplete rather than evidence of an absence of short sellers.
• Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast to a $(3.53) loss from $(3.42), cut Q3 2026 EPS to $(0.90) from $(0.87), and reduced Q4 2026 EPS to $(0.93) from $(0.90). These revisions point to weaker-than-previously-expected profitability and could limit gains despite the bullish price target.

Cullinan Therapeutics Stock Down 0.2%

CGEM opened at $19.60 on Thursday. The firm's 50 day moving average is $16.81 and its 200-day moving average is $14.99. Cullinan Therapeutics, Inc. has a 52-week low of $5.68 and a 52-week high of $19.94. The firm has a market capitalization of $1.26 billion, a P/E ratio of -6.32 and a beta of 0.01.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.01). Equities analysts expect that Cullinan Therapeutics, Inc. will post -3.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on CGEM. Wedbush restated an "outperform" rating and issued a $37.00 price target on shares of Cullinan Therapeutics in a report on Thursday, June 11th. Wall Street Zen lowered shares of Cullinan Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 1st. Weiss Ratings reissued a "sell (d-)" rating on shares of Cullinan Therapeutics in a research note on Wednesday, July 8th. BTIG Research lifted their target price on shares of Cullinan Therapeutics from $38.00 to $39.00 and gave the company a "buy" rating in a report on Wednesday, July 29th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $30.00 price target on shares of Cullinan Therapeutics in a research report on Monday, June 8th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Cullinan Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $32.14.

Read Our Latest Stock Analysis on CGEM

Cullinan Therapeutics Company Profile

(Free Report)

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.

Featured Articles

• Five stocks we like better than Cullinan Therapeutics
• GE Vernova’s AI Power Boom Faces a Profit Test
• Cardinal Health Earnings: Can Perfection Get Priced In Twice?
• Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
• Legacy Jet Builders Stall While Embraer Accelerates to New Highs

Want to see what other hedge funds are holding CGEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cullinan Therapeutics Right Now?

Before you consider Cullinan Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cullinan Therapeutics wasn't on the list.

While Cullinan Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here